Virtual trial shows that prophylactic Tamoxifen prevents breast cancer
Research published in the highly regarded scientific journal “Cancer” has shown that for certain women, order Tamoxifen, viagra buy a drug normally used to treat breast cancer, could have a preventative effect.
Not only that, but this pre-emptive treatment saves money.
Lead author, Peter Alperin and his colleagues at Archimedes Inc are healthcare modellers. Using complex mathematical models they create a virtual population of post-menopausal women and entered them into a virtual trial.
Unlike a real clinical trial there were no consent forms or ethics committees, so the costs and risks, both ethically and practically, were considerably lower than a real trial.
Alperin looked at the effect of preventative tamoxifen treatment in women who were healthy, but with a known statistical risk of developing breast cancer.
Tamoxifen is avery effective drug but in some patients has a high-risk side effect profile, and can cause pulmonary embolism, endometrial cancer, deep vein thrombosis and early menopause”
Alperin discovered that in a specific sub-group of women, who were post-menopausal, under 55 and with a statistical liklihood of developing cancer at 1.6% or greater, prophylactic Tamoxifen was a good option.
“In this group of women, using tamoxifen to prevent breast cancer saves lives and has a low frequency of side effects,” he said.
“Specifically”, he continued, “chemoprevention with tamoxifen prevents 29 breast cancer cases and 9 breast cancer deaths per 1,000 women treated”
Using the data collected in the virtual trial they were also able to predict that such preventative use of Tamoxifen would save money $47,580 per 1,000 women treated in the United States.












